Emcure Pharmaceuticals Ltd
NSE:EMCURE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oberoi Realty Ltd
NSE:OBEROIRLTY
|
IN |
Emcure Pharmaceuticals Ltd
Free Cash Flow
Emcure Pharmaceuticals Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
Free Cash Flow
₹4.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Free Cash Flow
₹18.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Free Cash Flow
₹27B
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Free Cash Flow
₹89B
|
CAGR 3-Years
53%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Free Cash Flow
₹29.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Free Cash Flow
₹13.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Emcure Pharmaceuticals Ltd
Glance View
Emcure Pharmaceuticals Ltd. emerged as a prominent player in the Indian pharmaceutical landscape, guided by a commitment to innovation and accessibility. Founded in 1981 by Satish Mehta, the company started as a small-scale manufacturer and has since evolved into a global pharmaceutical powerhouse. Emcure thrives on a multifaceted business model that encompasses the complete pharmaceutical value chain, from research and development to manufacturing and distribution. The company's success rests on its robust portfolio of generics, branded generics, and biopharmaceuticals, which cater to diverse therapeutic areas like cardiology, oncology, gynecology, and infectious diseases. The driving force behind Emcure's financial engine is its ability to balance volume and value. Through a network of state-of-the-art facilities, Emcure sustains a strong presence both domestically and internationally, with exports spanning over 70 countries. The firm capitalizes on economies of scale by leveraging its extensive production infrastructure, allowing it to offer high-quality medications at competitive prices. Furthermore, strategic collaborations and licensing agreements empower Emcure to penetrate new markets and broaden its product offerings. By continually expanding its pipeline and embracing cutting-edge technologies, Emcure not only secures its position in the competitive pharmaceutical industry but also reinforces its mission to deliver affordable healthcare solutions globally.
See Also
What is Emcure Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
4.4B
INR
Based on the financial report for Mar 31, 2025, Emcure Pharmaceuticals Ltd's Free Cash Flow amounts to 4.4B INR.
What is Emcure Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-9%
Over the last year, the Free Cash Flow growth was -44%. The average annual Free Cash Flow growth rates for Emcure Pharmaceuticals Ltd have been -9% over the past three years .